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Abstract Demyelination underlies early neurological symp-
toms in multiple sclerosis (MS); however, axonal damage is
considered critical for permanent chronic deficits. The precise
mechanisms by which axonal injury occurs in MS are unclear;
one hypothesis is the absence or failure of remyelination, sug-
gesting that promoting remyelination may protect axons from
death. This report provides direct evidence that promoting oligo-
dendrocyte remyelination protects axons and maintains transport
function. Persistent Theiler’s virus infection of Swiss Jim
Lambert (SJL)/J mice was used as a model of MS to assess the
effects of remyelination on axonal injury following demyelin-
ation in the spinal cord. Remyelination was induced using an
oligodendrocyte/myelin-specific recombinant human monoclo-
nal IgM, rHIgM22. The antibody is endowed with strong anti-
apoptotic and pro-proliferative effects on oligodendrocyte pro-
genitor cells. We used 1H-magnetic resonance spectroscopy
(MRS) at the brainstem to measure N-acetyl-aspartate (NAA)
as a surrogate of neuronal health and spinal cord integrity. We
found increased brainstem NAA concentrations at 5 weeks post-
treatmentwith rHIgM22,which remained stable out to 10weeks.
Detailed spinal cord morphology studies revealed enhanced
remyelination in the rHIgM22-treated group but not in the
isotype control antibody- or saline-treated groups. Importantly,
we found rHIgM22-mediated remyelination protected small- and
medium-caliber mid-thoracic spinal cord axons from damage
despite similar demyelination and inflammation across all exper-
imental groups. The most direct confirmation of remyelination-
mediated protection of descending neurons was an improvement
in retrograde transport. Treatment with rHIgM22 significantly
increased the number of retrograde-labeled neurons in the
brainstem, indicating that preserved axons are functionally com-
petent. This is direct validation that remyelination preserves spi-
nal cord axons and protects functional axon integrity.
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Introduction
The conduction of electrical impulses through long axonal
segments of the neuron is essential for proper functioning
of the central nervous system (CNS). Oligodendrocytes
produce myelin [1], which ensheath axons and integrally
support in fast axonal conduction. In multiple sclerosis
(MS), a chronic inflammatory demyelination of the CNS,
conduction block in demyelinated axons is responsible for
early neurological deficits, while axonal transection and
accumulating neuronal loss underlie permanent disability
[2, 3]. Endogenous myelin repair (remyelination) occurs
spontaneously in early lesions and restores secure conduc-
tion [3]; however, this process is hampered as disease ad-
vances [4]. In experimental models, induction of
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oligodendrocyte apoptosis causes demyelination, myelin
splitting, and/or vacuolization resulting in motor patholo-
gies of variable severity [5–7]. In chronic rat experimental
autoimmune encephalomyelitis (EAE), axon loss in the spi-
nal cord determined permanent neurological disability [8].
Demyelinated axons are vulnerable to further degeneration/
transection [9] as the mutual supply of trophic and metabol-
ic support between oligodendrocytes and the underlying
axons is lost. This suggests that repairing persistent demy-
elination may ameliorate clinical deterioration and may de-
crease axonal degeneration. In support of this concept,
Kornek et al. showed that remyelinated MS shadow plaques
had significantly less evidence of axonal injury compared
to inactive demyelinated lesions [10]. Likewise, Totoiu
et al. showed an association of axon sparing and a recovery
of function after transplant-mediated remyelination in the
mouse hepatitis virus-induced model of demyelination
[11]. Therefore, strategies to promote remyelination either
by transplantation of exogenous progenitors or targeting
endogenous ones to enhance remyelination may protect
axons. Our laboratory developed a recombinant human
monoclonal IgM antibody, rHIgM22, which binds specifi-
cally to live oligodendrocytes and myelin and promotes
remyelination in mouse models of MS [12–14]. This IgM
is a true human natural antibody and belongs to the normal
human germline immunoglobulin repertoire [15, 16].
rHIgM22 is self-reactive, but is non-toxic even at 4000
times the therapeutic dose [14]. rHIgM22 recently complet-
ed a 16-site phase I clinical trial in patients with MS with
complete safety [17].
Based on epidemiological evidence, viral infections are
thought to play a role in the initiation and/or exacerbation of
MS [18, 19]. Theiler’s murine encephalomyelitis virus
(TMEV), a single-stranded RNA virus belonging to the
Picornaviridae family, induces inflammatory demyelinating
disease in the spinal cord of susceptible strains of mice fol-
lowing infection [20]. TMEV-induced demyelinating disease
(TMEV-IDD) is a natural chronic-progressive CNS demyelin-
ating disease of susceptible strains of mice, with similarities to
primary progressive MS (reviewed in [21]). Demyelination in
association with an intense inflammatory response begins in
the spinal cord around day 21 following infection and is well
established by day 45. Demyelination in infected mice con-
tinues to worsen until approximately 90–100 days post-
infection (dpi), then reaches a plateau [22]. Retrograde label-
ing studies of demyelinated spinal cord axons performed in
our laboratory [23] revealed a reduction in labeled neuron cell
bodies in the brainstem that indicated death or dysfunction.
Magnetic resonance spectroscopy (MRS) is a non-invasive
tool to measure and quantify tissue metabolites. N-Acetyl-as-
partate (NAA), a derivative of aspartic acid, is found in high
concentrations in all areas of the brain, but is undetectable in
non-neuronal tissue. NAA is the second most abundant free
amino acid metabolite in the nervous tissue after glutamate
and provides a prominent peak in MRS readouts in vivo
[24]. NAA levels are reduced under numerous neuropatholog-
ical conditions such as brain injury, stroke, and Alzheimer’s
disease. Reduced NAA concentrations also correlated with
reduced axonal numbers in lesions of secondary progressive
MS (SPMS) patients [25], primary progressive MS (PPMS),
and relapsing remitting MS (RRMS) [26]. Therefore, NAA is
a key metabolite marker for neuronal health, viability, and
number [27]. Consequently, spontaneously remyelinating
mouse strains recover brainstem NAA concentrations [28],
whereas non-remyelinating mouse strains do not show recov-
ery of NAA concentrations [29]. We demonstrated that MRS
measurements of NAA at the brainstem reflects the integrity
of many ascending and descending spinal cord pathways
whose neuronal cell bodies lie in the brainstem, thus highlight-
ing the use of brainstem NAA concentrations as a surrogate
marker for spinal cord pathological changes, including demy-
elination and remyelination [29].
To date, there is no direct evidence that IgM-mediated
remyelination protects demyelinated axons from degeneration
in a progressive model of MS. To address this issue, we treated
TMEV-infected Swiss Jim Lambert (SJL) mice with rHIgM22
or controls at 90 dpi to monitor axon loss. This time point was
chosen because it is the beginning of axon loss, but without
complete loss of axon function, such that recovery of axonal
loss/functionmay occur. In addition, at 90 dpi, demyelination is
evident and brainstem NAA concentrations are significantly
lower compared to their baseline levels prior to infection [29].
We previously reported that the extent of remyelination induced
by rHIgM22 reaches maximal levels by 5 weeks after treatment
and remains out to 10 weeks [14]. By adopting this approach,
we postulated that rHIgM22-mediated remyelination protects
denuded axons from further destruction.
Materials and Methods
Ethics Statements
The Mayo Clinic Institutional Animal Care and Use
Committee (IACUC) approved all animal protocols used in
this study.
Theiler’s Virus-Induced Demyelinating Disease Model
(TMEV-IDD)
Six- to 8-week-old SJL/J (prototypic susceptible strain—H-2s)
mice were purchased from the Jackson Laboratories (Bar
Harbor, ME). Mice were anesthetized and intracerebrally
injected at 8 weeks of age with 2×105 plaque-forming units
(p.f.u.) of the Daniel’s strain of TMEV in a 10-μl volume. This
resulted in >98% incidence of infection with rare fatalities. The
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clinical disease course of identically aged mice and treatment
strategy are previously published [30, 31]. Mice in this study
developed observable gait deficits by 90 days post-infection
and were considered representative of the disease model.
Antibody Treatment
SJL mice at 90 dpi were treated with a single 100-μg intraper-
itoneal dose of rHIgM22 (N=11) or control IgM (N=10) dis-
solved in phosphate buffered saline (PBS) or 500 μl of the
vehicle, PBS (N=11), alone. Uninfected mice (N=3) were
used as a reference for retrograde labeling studies (see below).
Magnetic Resonance Spectroscopy
MRS was performed using a Bruker Avance 300 MHz (7T)
vertical bore NMR spectrometer (Bruker Biospin, Billerica,
MA). During data acquisition, animal core temperatures were
maintained at 37 °C by a flow of warm air. Inhalational
isoflurane anesthesia 1.5–2.5 % in oxygen was delivered via
a nose cone. MRS data were obtained and quantified from a
(2.5×2.5×2.5)mm3 voxel (15.625 μl), placed over the
brainstem as reported previously [29]. The brainstem was
chosen for study since many of the neuronal cell bodies of
descending and ascending spinal cord axons are present at this
site. MRS data was collected from each mouse before treat-
ment and at 5 and 10 weeks later. The same investigator se-
lected all voxels based on anatomical landmarks to maintain
strict uniformity. Bruker’s VSEL sequence, an implementa-
tion of the standard PRESS sequence, was used for voxel-
based spectroscopy, with built-in water suppression pulses.
Spinal Cord Morphometry
We assessed spinal cord morphometry in all groups 10 weeks
following treatment. Mice were anesthetized with sodium
pentobarbital and perfused intracardially with Trump’s fixa-
tive (phosphate-buffered 4 % formaldehyde/1 % glutaralde-
hyde, pH 7.4). Spinal cords were removed and sectioned pre-
cisely into 1-mm blocks. In order to represent the samples
along the length of the spinal cord, every third block was
post-fixed, stained with osmium tetroxide, and embedded in
araldite plastic (Polysciences, Warrington, PA). One-micron
sections were cut and stained with 4 % p-phenylenediamine
to visualize the myelin sheaths. We examined ten spinal cord
cross sections, spanning the entire spinal cord from the cervi-
cal to the distal lumbar regions, from each mouse. Each spinal
cord quadrant from every coronal section was graded for the
presence of inflammation, demyelination, and remyelination.
Areas of demyelination were characterized by naked axons,
cellular infiltration, and macrophages with engulfed myelin
debris. Abnormally thin myelin sheaths relative to axonal di-
ameter and absence of Schwann cells are indicative of
oligodendrocyte remyelination. Thick myelin sheaths and
the one-to-one relationship between axons and Schwann cells
identify Schwann cell remyelination. Areas of demyelination
and remyelination are well demarcated and allow accurate
quantitative assessment at ×10 and ×40 magnifications, re-
spectively. Demyelination scores were expressed as the per-
centage of spinal cord quadrants examined with pathological
abnormality. A maximum score of 100 indicated pathological
abnormality in every quadrant of all spinal cord sections of a
given mouse. A spinal cord quadrant was considered to be
remyelinated if greater than 75 % of the area of the field
contained remyelination. Remyelination scores were calculat-
ed as the ratio (%) of spinal cord quadrants with remyelination
over the number of spinal cord quadrants with pathologic
white matter abnormalities (demyelination), which had the
potential to be remyelinated. All grading were performed on
coded sections without knowledge of the experimental group.
To quantify myelinated axons, a mid-thoracic (T6) spinal
cord section from each animal was examined. This level of the
cord was chosen because it contains both ascending and de-
scending axons with neuronal soma in the brainstem [32]. To
ensure a uniform intensity of myelin labeling, all spinal cord
T6 sections used in the study were stained with the same batch
of 4 % para-phenylenediamine for exactly 20 min. An
Olympus Provis AX70 microscope and a ×60 oil immersion
objective were used to capture six sample areas of normal-
appearing white matter without demyelination from each sec-
tion. The six fields were collected in a clockwise manner
around the section to obtain representative samplings of the
posterior-lateral, antero-lateral, and anterior columns. Images
were centered between the gray matter and meningeal surface.
Approximately 400,000 μm2 of white matter was sampled
from each mouse. Absolute myelinated axon numbers were
measured using automated counting software that recognizes
circular intact myelin sheathes and calculated as reported [29].
Data were represented as the absolute number of all axons
sampled per mid-thoracic spinal cord section. All values were
averaged per group.
Brain Pathology
Brain pathology was assessed after the last MRS measure-
ment, using our previously described technique [33].
Following perfusion with Trump’s fixative, we made two cor-
onal cuts in the intact brain at the time of removal from the
skull (one section through the optic chiasm and a second sec-
tion through the infundibulum). We used the Atlas of the
Mouse Brain and Spinal Cord corresponding to sections 220
and 350, page 6 [34], as a guide. This resulted in three blocks
that were then embedded in paraffin. This allowed for system-
atic analysis of the pathology of the cortex, corpus callosum,
hippocampus, brain stem, striatum, and cerebellum. Resulting
sections were then stained with hematoxylin and eosin.
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Pathological scores were assigned without knowledge of ex-
perimental group to the different areas of the brain. Each area
of the brain was graded on a five-point scale as follows: 0, no
pathology; 1, no tissue destruction with only minimal inflam-
mation; 2, early tissue destruction (loss of architecture) and
moderate inflammation; 3, definite tissue destruction (demye-
lination, parenchymal damage, cell death, neurophagia, neu-
ronal vacuolation); and 4, necrosis (complete loss of all tissue
elements with associated cellular debris). Meningeal inflam-
mation was assessed and graded as follows: 0, no inflamma-
tion; 1, one cell layer of inflammation; 2, two cell layers of
inflammation; 3, three cell layers of inflammation; and 4, four
or more cell layers of inflammation. The area with maximal
tissue damage was used for assessment of each brain region.
Retrograde Labeling
Retrograde labeling was performed on a separate cohort of
mice (N=23; uninfected=3, rHIgM22=9, PBS=11), 9 weeks
after antibody treatment as described [23]. Seven days after
surgery, mice were sacrificed, perfused with 4 % paraformal-
dehyde, and brains and spinal cords collected. Serial
vibratome (Lancer Series 1200) sections (40 μm thick) of
the brainstem were collected and mounted under Vectashield
(Vector Laboratories Inc., Burlingame, CA). Cell bodies con-
taining retrograde tracer (FluoroGold), visualized by UV illu-
mination (360–370 nm excitation, 420–460 nm emission)
were counted at ×200 from 16 brainstem slices that encom-
pass the 2.5-mm brainstem voxel used to measure NAA con-
centrations. A cell was counted as positive if a large cross
section of the cell body was labeled with FluoroGold. The
number of labeled cell bodies in the brain stem nuclei reflected
the number of healthy and functional axons in the spinal cord.
All analyses were performed without knowledge of the exper-
imental group.
Graphs and Statistics
All graphs were plotted on GraphPad Prism v5.1 (GraphPad
Software, Inc., La Jolla, CA, USA). Statistics were computed
using SigmaPlot v11.0 (Systat Software, Inc., San Jose, CA,
USA). Results were compared by two-tailed Student’s t test if
normally distributed or by Mann–Whitney rank sum test if
non-normally distributed. We used one-way ANOVA for
comparing normally distributed data sets for more than two
groups or Kruskal–Wallis ANOVA on Ranks if data was non-
normally distributed. In all analyses, p<0.05 was considered
as statistically significant. Correlation coefficients between
paired sets of data were determined using the Pearson product
moment correlation. Fisher’s exact test was used to compare
animals with improved NAA versus those with no change/
decrease in NAA levels.
Results
A Single Peripheral Dose of rHIgM22 Administered
at 90 Days Post-TMEV Infection Improves Brainstem
NAA Concentrations at 5 and 10 Weeks Post-treatment
Brainstem NAA concentrations were evaluated as a measure
of overall spinal cord neuronal health. Brainstem NAA con-
centrations in uninfected healthy mice were 9.34±0.04 (mean
±SEM; N=6). Following TMEV infection, mice were divided
into three random groups and all have similar baseline NAA
concentrations at 90 dpi. The natural human IgM, rHIgM22,
enhances remyelination in TMEV-infected SJL mice [14]. To
investigate whether antibody-mediated remyelination protects
denuded axons from further destruction and improves
brainstem NAA concentrations, we treated groups of
TMEV-infected SJL mice at 90 dpi with a single 100-μg dose
of rHIgM22 (N=11), a non-CNS-reactive control IgM (N=
10) [35] or saline (N=11). At 5 and 10 weeks post-treatment,
NAA concentrations in the rHIgM22 were 9.48±0.30 and
9.51±0.36, respectively. Conversely, NAA concentrations in
the control groups were 8.81±0.28 (control IgM) and 8.24±
0.34 (saline) at 5 weeks post-treatment and 8.30±0.14 (control
IgM) and 7.92±0.38 (saline) at 10 weeks post-treatment. Our
results show that only the rHIgM22-treated mice exhibited a
significant increase in NAA concentrations at later time points
(p<0.005, one-way ANOVA), whereas in saline and control
IgM-treated mice, NAA concentrations remained unchanged
at the 5-week point or decreased at the 10-week time point
(Fig. 1a). Animals with improved NAA concentrations at
10 weeks after treatment were then compared to animals with
no change/decrease in NAA (Fig. 1b). NAA concentrations
were considered improved if the difference (NAA10 weeks−
NAAbaseline) was greater than or equal to two times the base-
line SEM. We found that 73 % (8 of 11 animals) of the
rHIgM22-treated group showed improved concentrations of
NAA compared to 10 % (1 of 10 animals) of the control IgM-
treated group or 9 % (1 of 11 animals) of the saline-treated
group. A Fisher’s exact test revealed the control IgM-treated
group did not differ from the saline-treated group (p=0.94),
whereas the rHIgM22-treated group differed from both con-
trol groups (p=0.008 and p=0.008, respectively).
Impact of Brain Pathology on rHIgM22-Mediated
Improvement of Brainstem NAA Concentrations
To test the possibility that variability in brainstem pathology
influenced NAA concentrations, we analyzed brainstem path-
ological scores across groups and found consistent minimal
disease (Fig. 1c). In addition, individual NAA concentrations
did not correlate with brainstem pathology (p=0.51, Fig. 1d).
Taken together, these results rule out the possibility that local
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brainstem pathology affects NAA concentration within the
measured voxel.
rHIgM22 Promotes CNS Remyelination in TMEV-IDD
Following the final MRS scan, spinal cords were removed,
embedded in plastic, sectioned at 10 levels representing the
entire cord, and stained with para-phenylenediamine to visu-
alize myelin sheaths. Ten sections from each cord were scored
for inflammation, demyelination, and remyelination. All treat-
ment groups showed equivalent levels of inflammation and
demyelination (Fig. 2a). However, only mice treated with
rHIgM22 showed enhanced remyelination (Fig. 2a).
Examples of typical demyelinated (Fig. 2b) and remyelinated
(Fig. 2c) lesions are shown.
rHIgM22 Treatment Preserves Spinal Cord Axons
We determined the number of myelinated axons from mid-
thoracic (T6) spinal cord sections. Axon counts from unin-
fected mice averaged 21,285±830 (mean±SEM). As expect-
ed, TMEV-IDD resulted in axon loss at 10 weeks post-
infection (Table 1). However, when the total number of
mid-thoracic myelinated axons was compared across treat-
ment groups, the rHIgM22-treated mice, with improved
NAA concentrations, also contained more axons than
Fig. 1 A single dose of rHIgM22 improves brainstem NAA
concentrations. Brainstem MRS was collected from TMEV-infected
SJL mice at 90 days post-infection prior to treatment, and at 5 and
10 weeks after treatment. a In the rHIgM22-treated group, NAA levels
increased at 5 and 10 weeks to 9.51 mM (p=0.025 and p=0.04, respec-
tively, one-way ANOVA repeated measures). In a saline-treated group, at
5 weeks, NAA concentrations dropped, and by 10 weeks were signifi-
cantly lower (p=0.077 and p=0.012, respectively, one-way ANOVA re-
peated measures). In the control IgM-treated group, no significant differ-
ence in NAA concentrations (p=0.17) was found. Initial NAA concen-
trations were not different across groups (p=0.76, one-way ANOVA).
The thick-dashed cayenne colored line represents the average baseline
NAA concentrations from uninfected healthy mice (N=6) and the thin
dotted black colored line represents the average baseline NAA concen-
trations from all treatment groups. Symbols represent the treatment
groups: rHIgM22 (red triangles), control IgM (blue circles), and saline
(green boxes). b Changes in individual NAA concentrations were calcu-
lated at the 10-week point versus before treatment. NAA levels were
considered improved if the difference (NAA10 weeks−NAAbefore) was
greater than or equal to two times the baseline SEM. NAA levels im-
proved in 1 of 10 in the control IgM-treated group, 1 of 11 in the saline-
treated group, and 8 of 11 in the rHIgM22-treated group. c Brainstem
pathological scores (means±SEM) were similar across treatment groups
(p=0.43). d The individual brainstem NAA concentration plotted against
the brainstem pathological score showed no correlation (p=0.51), *p
< 0.005, one-way ANOVA
Mol Neurobiol (2016) 53:5217–5228 5221
control IgM- and saline-treated groups (Table 1) suggesting
relative axon protection. We then performed a detailed anal-
ysis of axon distribution (Fig. 3a), which revealed a greater
preservation of both small-caliber (1–3.99 m2, Fig. 3b) and
medium-caliber (4–10 m2, Fig. 3c) axons in rHIgM22-
treated mice, whereas large-caliber axons (>10 m2, Fig. 3d)
were equivalent across all treatment groups (p=0.55, one-
way ANOVA). Furthermore, when we plotted individual
brainstem NAA concentrations against the total number of
mid-thoracic axons (Fig. 3e) and medium-caliber axons
(Fig. 3g), we found a positive and statistically significant
correlation (R2=0.19; p=0.013 and R2=0.23; p=0.005, re-
spectively). We did not find significant correlations between
NAA concentrations and small-caliber (Fig. 3f) or large-
caliber (Fig. 3h) axons.
rHIgM22 Preserves Axon Transport
Retrograde labeling relies on both anatomically continuous
axons and preserved retrograde transport mechanisms to pro-
vide an assessment of axonal integrity. Because MRS studies
showed no differences between saline and control IgM-
treated TMEV-infected mice, we studied only the saline
treatment as a control group for these experiments. One
week post-surgery (i.e., 10 weeks post-treatment), mice were
sacrificed and brains and spinal cords were collected. As a
reference, retrograde labeling was performed in age-matched
uninfected mice. Figure 4a shows an example of a cluster of
fluorescently labeled neurons in the brainstem, where cell
bodies as well as dendrites and axons are clearly seen. For
each descending neuron population, cell bodies containing
retrogradely transported label were quantified. All uninfect-
ed mice (N=3) had similar levels of labeling and presented
with an average number of 2983±39 (mean±SEM) labeled
brainstem neurons. We previously reported that retrograde
labeling studies performed in demyelinated mice demon-
strated a large reduction in fluorescently labeled neuron cell
bodies in the brainstem [23]. Similarly, we found that the
control-treated animals (N=11, 1185±98) and rHIgM22-
treated animals (N=9, 1599±99) had fewer labeled neurons
compared to uninfected mice. However, we found on an
average more fluorescently labeled brainstem neurons in
the rHIgM22 group compared to the saline group (p=
0.011, t test, two-tailed) (Fig. 4b). We again determined
axons from the mid-thoracic (T6) spinal cord sections in this
cohort. We found more axons in the rHIgM22-treated group
that tended towards significance compared to the saline-
treated group (15,137±517 versus 13,758±575, p=0.07).
When we plotted individual retrograde-labeled neurons as
Fig. 2 rHIgM22 promotes spinal cord remyelination. Data is expressed
as a percentage of quadrants with the pathological abnormality as a
function of all spinal cord quadrants examined. After the last MRS
scan, 10 weeks post-treatment, mice were sacrificed, and spinal cords
were removed and processed for morphologic analysis. a Mice from all
three treatment groups showed similar levels of spinal cord inflammation
and demyelination pathology. rHIgM22 treatment increased the extent of
remyelination as compared to control groups (p<0.001, one-way
ANOVA). Typical images of demyelination (b) and remyelination (c)
obtained from the antero-lateral spinal cord columns, areas with frequent
disease, are shown. Arrows represent examples of remyelinated axons
Table 1 A single dose of rHIgM22 protects axons in the spinal cord
















N number of animals
a The average±SEM of sampled myelinated axons per cross section
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a function of quantified axons of all calibers from all ani-
mals, irrespective of the treatment groups (Fig. 4c), we
found a positive and statistically significant correlation
(R2=0.24; p=0.008). Our results support the hypothesis that
a single treatment with rHIgM22 promoted remyelination
that directly protected spinal cord axons and indirectly
Fig. 3 A single dose of rHIgM22 preserves axons in the spinal cord.
When axons of all calibers were analyzed, a greater number were
counted in the rHIgM22-treated group as compared to the saline-treated
group (a). Symbols in a represent the treatment groups: rHIgM22 (red
triangles), control IgM (blue circles), and saline (green boxes). Consid-
ering axons of different calibers, a greater number of b small-caliber (1–
3.99 m2) and c medium-caliber (4–10 m2) axons were counted in the
spinal cords of rHIgM22-treated mice. The number of d large-caliber
axons (>10 m2) was not statistically different between groups of mice
(p=0.55). Bars represent the average of absolute number of myelinated
axons±SEM. eA positive correlation (p=0.013, R2=0.19) exists between
brainstem NAA concentrations collected at the 10-week time point from
all mice and the number ofmid-thoracic level axons. Individual brainstem
NAA concentrations are plotted against f small-caliber (p=0.11, R2=
0.08), g medium-caliber (p=0.005, R2=0.23), and h large-caliber (p=
0.4, R2=0.02) axons. Dotted lines represent 95 % confidence band of
the best-fit linear regression line
Fig. 4 rHIgM22 improves number of retrograde-labeled brainstem neu-
rons. FluoroGold-labeled neurons were counted in brainstem sections that
correspond to the (2.5×2.5×2.5)mm3 voxel used for collecting MRS
data. a Example of a cluster of fluorescently labeled neurons in the
brainstem is shown. Extensive labeling of cell bodies as well as axons
and dendrites can be easily appreciated. b The number of labeled neurons
in the uninfected mice (N=3) is shown as a reference. rHIgM22 treatment
increased the number of retrograde-labeled brainstem neurons compared
to the saline-treated group (p=0.011, t test). The average number of
retrograde-labeled brainstem neurons±SEM per treatment group is
shown. Symbols represent the treatment groups: rHIgM22 (red triangles)
and saline (green boxes). c Number of fluorescently labeled neurons
correlated positively and significantly to the number of axons (p=
0.008, R2=0.24)
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neuronal cell bodies in the brainstem, which may underlie
the increased brainstem NAA concentrations and enhanced
retrograde labeling.
Discussion
The aim of the current study was to investigate whether
remyelination protects axons following myelin denudation.
This was achieved by treating TMEV-infected mice demyelin-
ation with a remyelination-promoting human antibody,
rHIgM22. Our results show that improvement of remyelination
at 10 weeks post-treatment resulted in a significant increase of
brainstem NAA concentration. This is consistent with our pre-
vious observations where higher brainstem NAA concentra-
tions were measured in two different strains of mice that spon-
taneously remyelinate [28, 29]. In addition, we found that im-
proved remyelination correlated with a greater preservation of
spinal cord axons. This result strongly supports the concept that
remyelination protects axons from death. The number of spinal
cord axons correlated well with the corresponding increase in
brainstem NAA concentrations. Our analysis of spinal cord
axon distribution revealed that rHIgM22-mediated
remyelination primarily protected medium-caliber axons,
which correlated well with NAA concentrations in the
brainstem. However, large-diameter axons were not protected.
Possibly small- and medium-caliber axons were preferentially
remyelinated in this model. Alternatively, large-diameter axons
may shrink to become medium-diameter axons as a result of
injury and protected from further injury by remyelination.
The most direct evaluation of descending axon integri-
ty was retrograde labeling at the T6 level of the spinal
cord with the fluorescent tracer FluoroGold. Our results
show that demyelination in SJL mice is accompanied by a
reduction of axonal transport as detected by a decrease in
labeled brainstem neurons. The majority of demeylinated
lesions in the TMEV-IDD occur at the cervical and tho-
racic levels. Therefore, a reduction in the number of la-
beled brainstem cells occurs primarily because of dis-
turbed retrograde transport or axonal degeneration [22,
23]. Here, retrograde transport studies provided direct ev-
idence that rHIgM22-mediated remyelination protected
axon function in vivo. For efficient retrograde transport,
axons have to not only be present but also functionally
competent. Remyelination protected the function of spinal
cord axons and led to approximately 35 % more
FluoroGold-labeled brainstem neurons (Fig. 4b).
Antibody-induced remyelination was sufficient to protect
a significant number of axons from degeneration and pro-
moted spinal cord axonal transport function. In addition,
our data supports the concept that brainstem MRS may
serve as a reliable surrogate marker in clinical trials de-
signed to preserve or protect axons in the spinal cord.
The approach to remyelinate axons is considered to
be protective as axon survival depends on trophic sup-
port from myelin [36]. Data in a mouse model of chron-
ic demyelination indicates that mature glial cells pro-
duce various trophic factors that may aid in axonal sur-
vival long after myelin loss [37]. Positive correlations
between inflammatory activity of MS lesions and axon
damage provide support for immune-mediated axon de-
generation [38] and suggest that axons may be naïve
spectators in the surrounding inflammatory milieu dur-
ing active demyelination. Even though some anti-
inflammatory drugs may indirectly lead to a decrease
in axonal damage during inflammatory CNS disease,
no currently available drugs act directly on oligodendro-
cytes. The antibody described in this work, rHIgM22,
does not bind to neurons, or supports neurite extension
[13, 14], but acts on cells in the oligodendrocyte lineage
to enhance endogenous remyelination. Prineas et al. re-
cently showed that demyelination in human MS lesions
followed the loss of caspase 3-positive apoptotic oligo-
dendrocytes [39]. In this regard, we have evidence that
rHIgM22 prevents apoptotic signaling and inhibits oli-
godendrocyte differentiation by Lyn [40]. This implies
that rHIgM22-mediated remyelination is due to protec-
tion of oligodendrocyte progenitor cell (OPC) and oli-
godendrocytes rather than promotion of OPC differenti-
ation [40]. rHIgM22 stimulates OPC proliferation in
mixed glial cultures but not in purified OPCs.
Stimulation of OPC proliferation by rHIgM22 depends
on co-stimulatory astrocytic and/or microglial factors.
We demonstrated that rHIgM22-mediated activation of
PDGFalphaR is required for stimulation of OPC prolif-
eration. Taken together, our data indicates that rHIgM22
lowers the PDGF threshold required for OPC prolifera-
tion and protection, which can ultimately result in
remyelination of CNS lesions [41].
A number of lines of evidence support our conclusion that
oligodendrocyte function has a major effect on axonal integ-
rity. Oligodendrocytes play important roles in axon health and
survival through glial–axonal signaling. However, axonal in-
tegrity requires more than glia signaling molecules. In Plp1-
null mice lacking proteolipid protein (PLP), myelin assembly
seems to be normal, whereas natural Plp1 mutants, such as
jimpy and rumpshaker mice, exhibit dysmyelination caused
by the toxicity of a misfolded protein [42]. Pelizaeus-
Merzbacher disease (PMD) is an X-linked genetic disorder
in which multiplication, deletion, or missense mutations of
the plp1 gene lead to elevated expression of proteolipid pro-
te in 1 (PLP1), and subsequent ly mild to severe
dysmyelination-related symptoms [43]. In the later stages of
disease, absence of compact myelin as well as widespread
apoptosis of oligodendrocytes with superimposed axonal loss
are evident. More than one gene may be responsible for the
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support of axons by myelinating glia. For example, 2′,3′-cy-
clic nucleotide 3′-phosphodiesterase (CNP), one of the earliest
myelin-related proteins to be specifically expressed in differ-
entiating oligodendrocytes, binds to RNA and tubulin and
contributes to oligodendroglial process dynamics [44, 45].
Work done by Lappe-Siefke et al. indicated that CNP is es-
sential for oligodendroglial functions in axonal support and
myelination [46]. In addition, CNP is necessary for the forma-
tion of a normal inner tongue process of oligodendrocytes that
myelinate small-diameter axons. Indeed, axonal degeneration
in Cnp1 null mice is present very early in postnatal life [47].
Kang et al. demonstrated convincing oligodendrocyte dys-
function in both the motor cortex and spinal cord of amyotro-
phic lateral sclerosis (ALS) patients [48]. They hypothesized
that direct impairment of oligodendrocyte function results in
motor neuron vulnerability and faster disease progression.
Beattie et al. demonstrated p75-dependent apoptotic death of
oligodendrocytes in spinal cord injury [49]. Another group
demonstrated that remyelination by neural precursor cells con-
tributed to functional recovery in a rat model of spinal cord
injury [50]. rHIgM22-mediated reduction of caspase 3 activity
[40] on oligodendrocytes represents a novel therapeutic ap-
proach for many neurological diseases in which neurons and
axons degenerate, such as ALS, PMD, other demyelinating
and dysmyelinating diseases, and possibly spinal cord injury.
The above studies suggest that an improvement in oligo-
dendrocyte function (remyelination) may protect axonal integ-
rity. The goals of remyelination are neuroprotection, preven-
tion of neuronal dysfunction, and maintenance of functional
integrity of neurons and axons. The relevance of spontaneous
remyelination in recovery of function was demonstrated in a
cat model of demyelination with severe neurologic deficits
[51] and in mice with focal demyelinated lesions resulting
from ethidium bromide injection [52]. We demonstrated im-
proved neurological function associated with spontaneous
remyelination following extensive demyelination in the
TMEV model [53]. This study strengthens our earlier results
on remyelination but also demonstrates neuroprotection in the
TMEV-inducedmodel of inflammatory demyelinating disease
where axon loss is progressive. Spontaneous remyelination in
MS is generally limited [54, 55] with a block of adult OPC
differentiation into myelin-producing oligodendrocytes as one
potential reason [56]. Treatments to modulate this block to
myelination are likely of clinical value. The use of an antag-
onist to LINGO-1 highlighted the importance of regulation of
oligodendrocyte differentiation and myelination [57–59].
Correspondingly, treatment with anti-LINGO-1 antibody re-
sulted in spinal cord remyelination and improved axonal in-
tegrity in MOG-induced experimental autoimmune encepha-
lomyelitis [60] and lysolecithin-induced focal spinal cord de-
myelination in rats [61]. In another study, retinoid acid recep-
tor agonists (rexinoids) were used to successfully stimulate
OPC differentiation and promote remyelination of
demyelinated cerebellar slices and toxin-induced
demyelinated lesions in vivo [62].
Toxicity of the drug in vivo is a major issue for many
treatments to enter the market. The safety and tolerability of
single ascending dose of rHIgM22 was recently investigated
in a phase 1, multicenter, double-blind, randomized, placebo-
controlled, dose-escalation study in patients with MS [17]. No
dose-limiting toxicities or serious treatment-emergent adverse
events were reported at any rHIgM22 dose level [63].
rHIgM22 was measurable in the cerebrospinal fluid (CSF) in
all patients at day 2 and in a proportion of patients at day 29
following administration of a single dose. This observation
strongly supports the hypothesis that blood–brain/blood–
CSF barrier is permeable to CNS-modulating drugs across,
including large molecules such as IgM. Indeed, molecules as
large as IgM are present in normal CSF at approximately 1/
1000 of their serum concentration [64]. In the past, we used
non-invasive T2-weighted MRI studies and showed that
USPIO-labeled rHIgM22 antibody associated with a de-
creased spinal cord lesion load [65]. No IgM accumulation
in the CNS was apparent in non-infected animals or animals
without demyelination. Therapeutic approaches that aim to
boost intrinsic properties of progenitor cells or to supply pro-
genitors by cell transplantation approaches seek at promoting
remyelination and also to inhibit neurodegeneration.
However, a key question is whether the antibody- or cell-
based remyelination strategies offer a permanent solution.
Further studies to understand the mechanisms and complex
molecular factors that regulate remyelination should help an-
swer these concerns.
CNS, central nervous system; MRS, magnetic resonance
spectroscopy; MS, multiple sclerosis; NAA, N-acetyl-aspar-
tate; PPMS, primary progressive multiple sclerosis; rHIgM22,
recombinant human immunoglobulinM 22; RRMS, relapsing
remitting multiple sclerosis; SPMS, secondary progressive
multiple sclerosis; SJL, Swiss Jim Lambert; TMEV,
Theiler’s murine encephalomyelitis virus
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